IDMC recommends continuation of Phase III knee OA trial for Axsome's AXS-02

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended continuing the Phase III COAST-1 trial of AXS-02 (disodium zoledronate tetrahydrate) to treat

Read the full 210 word article

User Sign In